NCT07093944View on ClinicalTrials.gov

Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 9, 2018

Primary Completion Date

December 22, 2021

Study Completion Date

December 22, 2021

Conditions
Parkinson's Disease (PD)
Interventions
DRUG

N-Acetylcysteine (NAC) Treatment

Parkinson's disease patients receive NAC (1200 mg/day) for one year.

DRUG

Placebo

Parkinson's disease patients receive Placebo similar to the real drug, with no active ingredient

Trial Locations (1)

Unknown

Kurdistan University of Medical Sciences, Sanandaj

All Listed Sponsors
lead

Kurdistan University of Medical Sciences

OTHER

NCT07093944 - Randomized, Placebo-Controlled Trial of N-acetylcysteine In Parkinson's Disease Patients: A Pilot Study | Biotech Hunter | Biotech Hunter